Cardioprotective effect of carvedilol: inhibition of apoptosis in H9c2 cardiomyocytes via the TLR4/NF‑κB pathway following ischemia/reperfusion injury

Zhao,Yong; Xu,Yan; Zhang,Jianhua; Ji,Tingting

doi:10.3892/etm.2014.1863

Cardioprotective effect of carvedilol: inhibition of apoptosis in H9c2 cardiomyocytes via the TLR4/NF‑κB pathway following ischemia/reperfusion injury

Authors:
- Yong Zhao
- Yan Xu
- Jianhua Zhang
- Tingting Ji
View Affiliations

Affiliations: Department of Emergency, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Cardiovascular Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: July 24, 2014 https://doi.org/10.3892/etm.2014.1863
Pages: 1092-1096

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carvedilol is a non‑selective β‑blocker used in the treatment of cardiovascular disease, including myocardial ischemia. The aim of the present study was to investigate the molecular mechanisms underlying the effects of carvedilol on simulated ischemia/reperfusion (SI/R)‑induced cardiomyocyte apoptosis in vitro. H9c2 cardiomyocytes were incubated with either a vehicle or an ischemic buffer during hypoxia followed by reoxygenation with or without carvedilol. In two additional groups, toll‑like receptor 4 (TLR4) and nuclear factor κ-light-chain-enhancer of activated B cells (NF‑κB) were inhibited by a TLR4 antibody and pyrrolidine dithiocarbamate, respectively. The results revealed that carvedilol markedly decreased SI/R‑induced apoptosis in a concentration‑dependent manner, as demonstrated by flow‑cytometric analysis. This effect was shown to be associated with an increase in the B-cell lymphoma 2 (Bcl‑2)/Bcl-2-associated X (Bax) protein ratio and concurrent reductions in the expression levels of TLR4 and NF‑κB. These results suggest that carvedilol provides significant cardioprotection against SI/R‑induced injury in H9c2 cardiomyocytes, an effect likely to be mediated through the TLR4/NF‑κB signaling pathway.

View Figures

View References

1	Jayachandran M, Brunn GJ, Karnicki K, Miller RS, Owen WG and Miller VM: In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol (1985). 102:429–433. 2007. View Article : Google Scholar
2	Zhong X, Li X, Qian L, et al: Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats. J Biomed Res. 26:346–354. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lin J, Wang H, Li J, et al: κ-Opioid receptor stimulation modulates TLR4/NF-κB signaling in the rat heart subjected to ischemia-reperfusion. Cytokine. 61:842–848. 2013.
4	Kim SC, Stice JP, Chen L, et al: Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res. 105:1186–1195. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zhao P, Wang J, He L, et al: Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. J Cell Mol Med. 13:1513–1525. 2009. View Article : Google Scholar : PubMed/NCBI
6	Riad A, Jäger S, Sobirey M, et al: Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol. 180:6954–6961. 2008. View Article : Google Scholar : PubMed/NCBI
7	Leonetti G and Egan CG: Use of carvedilol in hypertension: an update. Vasc Health Risk Manag. 8:307–322. 2012.PubMed/NCBI
8	Kanoupakis EM, Manios EG, Mavrakis HE, et al: Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. Cardiovasc Drugs Ther. 22:169–176. 2008. View Article : Google Scholar : PubMed/NCBI
9	Le DE, Pascotto M, Leong-Poi H, Sari I, Micari A and Kaul S: Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol. 108:3842013. View Article : Google Scholar : PubMed/NCBI
10	Mori Y, Nishikawa Y, Kobayashi F and Hiramatsu K: Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. Int Heart J. 54:15–22. 2013.PubMed/NCBI
11	Chen-Scarabelli C, Saravolatz L Jr, Murad Y, et al: A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs. 12:391–401. 2012.PubMed/NCBI
12	Liu Q, Zhang J, Xu Y, Huang Y and Wu C: Effect of carvedilol on cardiomyocyte apoptosis in a rat model of myocardial infarction: a role for toll-like receptor 4. Indian J Pharmacol. 45:458–463. 2013. View Article : Google Scholar : PubMed/NCBI
13	Esumi K, Nishida M, Shaw D, Smith TW and Marsh JD: NADH measurements in adult rat myocytes during simulated ischemia. Am J Physiol. 260:H1743–1752. 1991.PubMed/NCBI
14	Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 357:1385–1390. 2001. View Article : Google Scholar : PubMed/NCBI
15	Jin YC, Kim CW, Kim YM, et al: Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. Eur J Pharmacol. 614:91–97. 2009.PubMed/NCBI
16	Lin E, Freedman JE and Beaulieu LM: Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther. 27:117–123. 2009. View Article : Google Scholar : PubMed/NCBI
17	Ishikawa Y, Satoh M, Itoh T, Minami Y, Takahashi Y and Akamura M: Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin Sci (Lond). 115:133–140. 2008. View Article : Google Scholar : PubMed/NCBI
18	Poole-Wilson PA, Swedberg K, Cleland JG, et al: Carvedilol Or Metoprolol European Trial Investigators: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 362:7–13. 2003. View Article : Google Scholar
19	Fiuzat M, Wojdyla D, Kitzman D, et al: Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 60:208–215. 2012. View Article : Google Scholar
20	Soriano ME and Scorrano L: Traveling Bax and forth from mitochondria to control apoptosis. Cell. 145:15–17. 2011. View Article : Google Scholar : PubMed/NCBI
21	Condorelli G, Morisco C, Stassi G, et al: Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation. 99:3071–3078. 1999. View Article : Google Scholar : PubMed/NCBI
22	Shimamoto A, Chong AJ, Yada M, et al: Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 114(1 Suppl): I270–I274. 2006. View Article : Google Scholar : PubMed/NCBI